Day: May 15, 2022

Orphazyme A/S in restructuringCompany announcementNo. 24/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355  KemPharm to acquire Orphazyme assets, including those relating to the development and approval of arimoclomol, for a total of USD 12.8 million in cash and assumed liabilities estimated to equal approximately USD 5.2 million The majority of Orphazyme’s approximately 20 current employees will become employees at KemPharm KemPharm intends to continue to pursue approval of arimoclomol as a treatment option for NPCOrphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC), announces today that it has signed an agreement to sell substantially all of the Company’s assets and business activities...

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 13 May 2022 acquired 38,419 shares in the Company at a price of NOK 84.63 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,038,419 shares in the Company, equivalent to 37.59% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.  AttachmentPrimary insider notification form

Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapyLatest results of the Phase 3 IKEMA trial demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in patients who relapsed after a prior therapy, including lenalidomide The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone Further analysis, following U.S. Food and Drug Administration recommendations on censoring rules, showed mPFS increased from 20.8 to 41.7 months when Sarclisa was added to carfilzomib and dexamethasonePARIS, May 15, 2022. Latest results from the Phase 3 IKEMA clinical trial evaluating Sarclisa® (isatuximab) in combination...